Brief Review of Ofatumumab versus Teriflunomide in Multiple Sclerosis— Hauser 2020

This is a brief audio review. In the article Ofatumumab versus Teriflunomide in Multiple Sclerosis. published, 2020 by Hauser and Colleagues, The outcomes and key points are as noted: Disability worsening, 3 months, 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P = 0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P = 0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P = 0.09). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups. This was a Phase 3, Randomized controlled trial, Double blinded (Double dummy) with 1882 patients who were Patients with multiple sclerosis. The Trial names were ASCLEPIOS I and ASCLEPIOS II Trial.

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. PMID: 32757523.